An Open-label Randomized Controlled Phase II Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia
AS1411, in combination with Cytarabine, targets patients with primary refractory or relapsed Acute Myeloid Leukemia (AML), a market characterized by high unmet medical need and limited treatment options. The study's termination suggests potential challenges in efficacy or safety, which may impact Antisoma Research's strategic positioning and investor confidence. The competitive landscape includes established therapies like Cytarabine and emerging agents, necessitating a thorough evaluation of AS1411's differentiation and market viability. Diligence should focus on the implications of trial outcomes on future development pathways and potential partnerships.
Indication: Acute Myeloid Leukemia
Modality: small molecule
Target: Nucleolin (as AS1411 is an aptamer targeting nucleolin)
Sponsor: Antisoma Research
Source URL: ClinicalTrials.gov
Source updated: Feb 02, 2011
Ingested: Jun 18, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Nucleolin (as AS1411 is an aptamer targeting nucleolin)
View original source fields
Condition raw: Acute Myeloid Leukemia
Condition normalized: Acute Myeloid Leukemia
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Nucleolin (as AS1411 is an aptamer targeting nucleolin)
Target normalized: Nucleolin (as AS1411 is an aptamer targeting nucleolin)